CEVOLUTION

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

What's the purpose of the trial?

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Trial status

Accepting patients

Phase
Phase 3
Enrollment
380
Last Updated

Participating Centers

There are 6 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Pomalidomide
  • Dexamethasone
  • Cevostamab
  • Daratumumab
  • Elotuzumab
  • Carfilzomib

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Cevostamab + Pomalidomide + Dexamethasone

Accepting patients

Standard of Care (SOC)

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.